David Westenberg
Stock Analyst at Piper Sandler
(4.02)
# 685
Out of 4,479 analysts
111
Total ratings
52.05%
Success rate
10.36%
Average return
Main Sectors:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELAN Elanco Animal Health | Maintains: Neutral | $19 → $16 | $14.01 | +14.20% | 8 | Jul 1, 2024 | |
| NTRA Natera | Maintains: Overweight | $110 → $120 | $110.70 | +8.40% | 10 | May 14, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $6.5 → $2 | $1.28 | +56.25% | 5 | May 13, 2024 | |
| CTKB Cytek Biosciences | Maintains: Overweight | $10 → $8.5 | $5.60 | +51.79% | 6 | May 13, 2024 | |
| ZTS Zoetis | Reiterates: Overweight | $220 → $195 | $174.81 | +11.55% | 7 | Apr 16, 2024 | |
| NEOG Neogen | Maintains: Neutral | $19 → $17 | $15.13 | +12.36% | 8 | Apr 15, 2024 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $28 → $25 | $19.98 | +25.13% | 5 | Mar 6, 2024 | |
| NEO NeoGenomics | Maintains: Overweight | $18 → $20 | $13.73 | +45.67% | 7 | Feb 26, 2024 | |
| GH Guardant Health | Maintains: Overweight | $40 → $30 | $28.87 | +3.91% | 6 | Feb 26, 2024 | |
| IDXX IDEXX Laboratories | Downgrades: Neutral | $525 | $477.23 | +10.01% | 5 | Jan 30, 2024 | |
| OCX OncoCyte | Maintains: Neutral | $3.5 → $3 | $2.96 | +1.35% | 7 | Nov 13, 2023 | |
| ILMN Illumina | Maintains: Overweight | $200 → $190 | $105.51 | +80.08% | 11 | Nov 13, 2023 | |
| AKYA Akoya Biosciences | Maintains: Overweight | $11 → $8 | $2.18 | +266.97% | 5 | Nov 13, 2023 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $13 → $6 | $3.37 | +78.04% | 7 | Nov 13, 2023 | |
| DGX Quest Diagnostics | Maintains: Neutral | $130 → $140 | $136.64 | +2.46% | 3 | Nov 6, 2023 | |
| EXAS Exact Sciences | Maintains: Overweight | $90 → $80 | $43.17 | +85.31% | 7 | Oct 16, 2023 | |
| PETQ PetIQ | Maintains: Buy | n/a | $22.59 | - | 1 | Jun 25, 2020 | |
| TXG 10x Genomics | Initiates: Buy | n/a | $18.87 | - | 1 | Mar 5, 2020 | |
| QDEL QuidelOrtho | Upgrades: Buy | n/a | $31.36 | - | 1 | Jan 4, 2018 | |
| TRUP Trupanion | Initiates: Neutral | n/a | $27.75 | - | 1 | Nov 21, 2017 |
Elanco Animal Health
Jul 1, 2024
Maintains: Neutral
Price Target: $19 → $16
Current: $14.01
Upside: +14.20%
Natera
May 14, 2024
Maintains: Overweight
Price Target: $110 → $120
Current: $110.70
Upside: +8.40%
Pacific Biosciences of California
May 13, 2024
Maintains: Neutral
Price Target: $6.5 → $2
Current: $1.28
Upside: +56.25%
Cytek Biosciences
May 13, 2024
Maintains: Overweight
Price Target: $10 → $8.5
Current: $5.60
Upside: +51.79%
Zoetis
Apr 16, 2024
Reiterates: Overweight
Price Target: $220 → $195
Current: $174.81
Upside: +11.55%
Neogen
Apr 15, 2024
Maintains: Neutral
Price Target: $19 → $17
Current: $15.13
Upside: +12.36%
Fulgent Genetics
Mar 6, 2024
Maintains: Neutral
Price Target: $28 → $25
Current: $19.98
Upside: +25.13%
NeoGenomics
Feb 26, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $13.73
Upside: +45.67%
Guardant Health
Feb 26, 2024
Maintains: Overweight
Price Target: $40 → $30
Current: $28.87
Upside: +3.91%
IDEXX Laboratories
Jan 30, 2024
Downgrades: Neutral
Price Target: $525
Current: $477.23
Upside: +10.01%
OncoCyte
Nov 13, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $2.96
Upside: +1.35%
Illumina
Nov 13, 2023
Maintains: Overweight
Price Target: $200 → $190
Current: $105.51
Upside: +80.08%
Akoya Biosciences
Nov 13, 2023
Maintains: Overweight
Price Target: $11 → $8
Current: $2.18
Upside: +266.97%
Adaptive Biotechnologies
Nov 13, 2023
Maintains: Overweight
Price Target: $13 → $6
Current: $3.37
Upside: +78.04%
Quest Diagnostics
Nov 6, 2023
Maintains: Neutral
Price Target: $130 → $140
Current: $136.64
Upside: +2.46%
Exact Sciences
Oct 16, 2023
Maintains: Overweight
Price Target: $90 → $80
Current: $43.17
Upside: +85.31%
PetIQ
Jun 25, 2020
Maintains: Buy
Price Target: n/a
Current: $22.59
Upside: -
10x Genomics
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $18.87
Upside: -
QuidelOrtho
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $31.36
Upside: -
Trupanion
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $27.75
Upside: -